JP6640716B2 - 細菌感染症を治療するための化合物及び方法 - Google Patents

細菌感染症を治療するための化合物及び方法 Download PDF

Info

Publication number
JP6640716B2
JP6640716B2 JP2016517061A JP2016517061A JP6640716B2 JP 6640716 B2 JP6640716 B2 JP 6640716B2 JP 2016517061 A JP2016517061 A JP 2016517061A JP 2016517061 A JP2016517061 A JP 2016517061A JP 6640716 B2 JP6640716 B2 JP 6640716B2
Authority
JP
Japan
Prior art keywords
group
optionally substituted
heterocycle
hydrocarbyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016517061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520618A (ja
JP2016520618A5 (cg-RX-API-DMAC7.html
Inventor
ジェイムズ・ダブリュー・ジャネトカ
ジェンフー・ハン
スコット・ハルトグレン
ジェリー・ピンクナー
コリン・クズマーノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2016520618A publication Critical patent/JP2016520618A/ja
Publication of JP2016520618A5 publication Critical patent/JP2016520618A5/ja
Application granted granted Critical
Publication of JP6640716B2 publication Critical patent/JP6640716B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016517061A 2013-05-30 2014-05-30 細菌感染症を治療するための化合物及び方法 Active JP6640716B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361828954P 2013-05-30 2013-05-30
US61/828,954 2013-05-30
PCT/US2014/040355 WO2014194270A1 (en) 2013-05-30 2014-05-30 Compounds and methods for treating bacterial infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019236676A Division JP2020073543A (ja) 2013-05-30 2019-12-26 細菌感染症を治療するための化合物及び方法

Publications (3)

Publication Number Publication Date
JP2016520618A JP2016520618A (ja) 2016-07-14
JP2016520618A5 JP2016520618A5 (cg-RX-API-DMAC7.html) 2017-07-06
JP6640716B2 true JP6640716B2 (ja) 2020-02-05

Family

ID=51989445

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016517061A Active JP6640716B2 (ja) 2013-05-30 2014-05-30 細菌感染症を治療するための化合物及び方法
JP2019236676A Pending JP2020073543A (ja) 2013-05-30 2019-12-26 細菌感染症を治療するための化合物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019236676A Pending JP2020073543A (ja) 2013-05-30 2019-12-26 細菌感染症を治療するための化合物及び方法

Country Status (9)

Country Link
US (4) US9957289B2 (cg-RX-API-DMAC7.html)
EP (1) EP3003322B1 (cg-RX-API-DMAC7.html)
JP (2) JP6640716B2 (cg-RX-API-DMAC7.html)
CN (2) CN105682665A (cg-RX-API-DMAC7.html)
AU (1) AU2014273962B2 (cg-RX-API-DMAC7.html)
CA (1) CA2913622A1 (cg-RX-API-DMAC7.html)
ES (1) ES2959183T3 (cg-RX-API-DMAC7.html)
HK (1) HK1225649A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014194270A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112008001301T5 (de) 2007-05-14 2010-04-29 Reserach Foundation Of State University Of New York Induktion einer physiologischen Dispersions-Antwort in Bakterien-Zellen in einem Biofilm
WO2012109263A1 (en) 2011-02-07 2012-08-16 The Washington University Mannoside compounds and methods of use thereof
CN105682665A (zh) 2013-05-30 2016-06-15 华盛顿大学 用于治疗细菌性感染的化合物和方法
EP3300500B9 (en) 2015-05-20 2021-01-13 Amgen Inc. Triazole agonists of the apj receptor
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
US10543223B2 (en) * 2015-08-05 2020-01-28 Enterome Mannose derivatives useful for treating pathologies associated with adherent E. coli
JP2019508504A (ja) * 2016-03-11 2019-03-28 フィンブリオン セラピューティックス， インコーポレイテッドＦｉｍｂｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 疾病の処置に有用なｃ−グリコシド化合物
CN108778288A (zh) * 2016-03-23 2018-11-09 菲姆布里昂医疗公司 可用于治疗疾病的FimH的甘露糖衍生的拮抗剂
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
EP3541804B1 (en) 2016-11-16 2025-01-22 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
JP6756925B2 (ja) 2017-01-11 2020-09-16 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼの二環式阻害剤
SMT202200232T1 (it) 2017-08-07 2022-07-21 Alkermes Inc Inibitori biciclici di istone deacetilasi
EP3697924A1 (en) 2017-10-16 2020-08-26 Enterome New tools for assessing fimh blockers therapeutic efficiency
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
PL3820856T3 (pl) 2018-07-10 2022-12-19 Glaxosmithkline Intellectual Property Development Limited Związki c-mannozydów przydatne w leczeniu zakażeń układu moczowego
CN109762034B (zh) * 2019-02-23 2022-04-29 福建医科大学 新型对苯二甲醛缩d-氨基葡萄糖席夫碱的制备方法
CN119143735A (zh) * 2019-05-07 2024-12-17 葛兰素史密斯克莱知识产权发展有限公司 新的化合物
US12351597B2 (en) 2019-06-19 2025-07-08 Glaxosmithkline Intellectual Property Development Limited Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of FimH
CA3164767A1 (en) * 2020-03-02 2021-09-10 Nimesh Patel A pharmaceutical composition and method of treatment using serratiopeptidase, mannose or its derivative, and optionally antinfection agents
CN113461753B (zh) 2020-03-31 2023-05-23 郑计岳 2-炔基甘露糖衍生物及其应用
CN113797212B (zh) * 2020-06-11 2023-12-22 兰州大学 一组含有甘露糖结构的抗菌药物的合成方法及活性研究
EP4247389A4 (en) * 2020-12-28 2024-10-09 Georgia Tech Research Corporation Glycosylated histone deacetylase inhibitors and methods of making and using the same
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
CN116023273A (zh) * 2023-03-29 2023-04-28 思合基因(北京)生物科技有限公司 一种新型碳糖苷及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122602A (en) 1989-02-13 1992-06-16 Miles Inc. Chromogenic merocyanine enzyme substrates
JPH09505309A (ja) 1993-11-18 1997-05-27 ワシントン・ユニバーシティ 細菌感染の治療および予防のための化合物および医薬組成物
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
AU7470300A (en) 1999-08-11 2001-03-05 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
ATE419880T1 (de) 2000-06-09 2009-01-15 Baylor College Medicine Kombination von antimikrobiellen wirkstoffen und bakterieller interferenz zum überziehen medizinischer vorrichtungen
WO2005033059A1 (es) 2003-10-08 2005-04-14 Innovaprotean, S.L. Compuestos útiles para el tratamiento de enfermedades asociadas a la formación de fibrilas amiloides
US20080171706A1 (en) * 2004-03-23 2008-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Anti-Adhesive Compounds to Prevent and Treat Bacterial Infections
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
FR2876798A1 (fr) 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
WO2012109263A1 (en) * 2011-02-07 2012-08-16 The Washington University Mannoside compounds and methods of use thereof
WO2011050323A1 (en) 2009-10-22 2011-04-28 The Washington University Compounds and methods for treating bacterial infections
EP2604619A3 (en) * 2009-12-14 2014-01-22 University of Basel Mannose derivatives as antagonists of bacterial adhesion
WO2012164074A1 (en) 2011-06-03 2012-12-06 University Of Basel Mannose phosphate derivatives as antagonists of bacterial adhesion
CN105682665A (zh) 2013-05-30 2016-06-15 华盛顿大学 用于治疗细菌性感染的化合物和方法

Also Published As

Publication number Publication date
US20180194792A1 (en) 2018-07-12
US9957289B2 (en) 2018-05-01
CN111423479A (zh) 2020-07-17
CA2913622A1 (en) 2014-12-04
WO2014194270A1 (en) 2014-12-04
JP2016520618A (ja) 2016-07-14
US20210122776A1 (en) 2021-04-29
AU2014273962B2 (en) 2019-07-25
AU2014273962A1 (en) 2015-12-17
US20160145289A1 (en) 2016-05-26
US20230033327A1 (en) 2023-02-02
EP3003322A1 (en) 2016-04-13
HK1225649A1 (zh) 2017-09-15
ES2959183T3 (es) 2024-02-21
CN105682665A (zh) 2016-06-15
EP3003322B1 (en) 2023-09-13
EP3003322A4 (en) 2017-01-25
JP2020073543A (ja) 2020-05-14
HK1223546A1 (en) 2017-08-04

Similar Documents

Publication Publication Date Title
JP6640716B2 (ja) 細菌感染症を治療するための化合物及び方法
EP2672820B1 (en) Mannoside compounds and methods of use thereof
EP3492483A1 (en) Compounds and methods for treating bacterial infections
CN112074507A (zh) 作为抗菌素的化合物
KR20090086611A (ko) 항박테리아 퀴놀린 유도체
JP7371838B2 (ja) 環縮合チアゾリノ２－ピリドン、それらの調製方法、ならびにグラム陽性菌が関与する疾患の治療および／または予防におけるそれらの使用
KR101329587B1 (ko) 항균제로서의 퀴놀린 유도체
KR101413094B1 (ko) 항박테리아제로서의 퀴놀린 유도체
HK40034028A (en) Compounds and methods for treating bacterial infections
HK1223546B (en) Mannose derivatives and their use in the treatment of bacterial infections
UA123790C2 (uk) Кристалічна форма (r)-4-(5-(циклопропілетиніл)ізоксазол-3-іл)-n-гідрокси-2-метил-2-(метилсульфоніл)бутанаміду як антибактеріального агента
JP5073948B2 (ja) 医薬組成物
RU2575477C2 (ru) Соединения для лечения заболеваний, связанных с clostridium difficile
HK40043214A (en) Compound acting as antibiotics
HK1122210B (en) Quinoline derivatives as antibacterial agents

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190723

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191226

R150 Certificate of patent or registration of utility model

Ref document number: 6640716

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250